The Odulair patent pending Ebola Patient Isolation Unit and Treatment Center is a turn-key solution that exceeds the CDC Ebola virus isolation, infection prevention and control recommendations for hospitalized patients with known or suspected Ebola hemorrhagic fever in U.S. hospitals. Our Unit design has been reviewed and positively vetted by healthcare teams treating Ebola patients in both West Africa and the United States.
The patent pending Ebola Isolation Ward is the world’s only facility that exceeds CDC recommendations by providing all three types of isolation required for proper containment of Ebola patients in addition to providing a safe haven protective environment for health care workers.
The Ebola isolation ward includes a self-contained option for locations without adequate power or biological hazard waste management.
We utilized our expertise in building negative and positively pressurized mobile clinics in order to design the ultimate highly contagious infection isolation unit to contain the Ebola virus and provide a protective environment for medical staff. We also protect the medical staff by incorporating the optional InTouch Health RP-VITA autonomous robot for telemedicine consults and to make deliveries of medications, oral rehydration fluids, and food to patients eliminating the need for medical staff to enter the patient room unnecessarily.
The Odulair Ebola Virus Isolation Unit includes a unique positively pressurized medical staff area providing a safe haven for your medical team. The Unit also includes a decontamination area for Ebola prevention and spreading the Ebola virus.
The Odulair Ebola Isolation Unit can be produced in tents for air freight deployment; shipping container units; modular buildings appropriate for U.S. and other hospitals, and double expandable trailers. The estimated build time for tents is 3 to 4 weeks, containers are 4 weeks, modular buildings are 4 to 6 weeks, and double expandable trailers are 3 to 4 months.
Whether you are interested in a building, container, or tent-based Odulair Ebola Isolation Unit, they are all designed as "modules" allowing for scalability from a minimum of 2 patients to as many as you need.
In rural locations where the likelihood of encountering an Ebola patient is greatly reduced, we recommend our Odulair Ebola Bedside Isolation Tent System. This unit converts any standard hospital room into an airborne infection isolation room to increase the containment level of the Ebola virus. With the addition of our Ebola Patient Transport Pod, your medical staff can safely transport the suspected patient to a more well-equipped Ebola patient facility.
The Ebola virus can be transmitted via contact with an infected patient's bodily fluids, airborne particulate epithelial cells, and with the virus suspended in aerosol moisture. Clinical studies performed by the U.S. Army in 1995 (1) and 2012 (2) also suggest that in cool, dry climates, the virus may exhibit airborne transmission. The patent-pending Odulair Ebola Isolation Unit provides virus containment that address all of these known and possible modes of transmission.
The most common mode of transmission is through direct contact with an Ebola patient or the patient's bodily fluids. The virus must reach broken skin or a mucous membrane, but that is almost unavoidable because the patient and everything they touch are contaminated for up to seven weeks.
The patent pending Odulair Ebola Isolation Unit utilizes a central decontamination room that provides a safe room to spray or wipe down people and equipment to inactivate the Ebola virus. The Unit also utilizes a specialized pass-thru autoclave to sterilize both human waste such as urine, feces, and shower water including sweat; and bagged biohazard waste such as clothing, linen, used consumables, needles, and anything contaminated with the Ebola virus eliminating the need for costly biohazard waste transport. The combination of the central decontamination room and the specialized autoclave provide complete isolation of bodily fluids and inactivation of the virus addressing the most common mode of Ebola transmission.
As the Ebola patient’s symptoms advance, they suffer from severe dehydration causing epithelial cells to flake off and float in the air. A lesser known form of transmission is via inhaling or allowing these microparticles to come in contact with mucous membranes. Although wearing a respirator in the hot zone decreases contact with these epithelial cells, it is not always 100% effective. The Odulair Ebola Isolation Unit incorporates two technologies to address this mode of transmission. The Unit utilizes the highest level of HEPA Type A filtration that is 99.99% effective at eliminating airborne particles down to 0.3 microns in size. Additionally, all isolation room air is treated with germicidal ultraviolet (UV) radiation, which has demonstrated effectiveness at inactivating the Ebola virus. This extra containment step helps to provide a safer environment for health care staff when they are working within the contaminated hot zone.
Ebola is also known to be transmittable via aerosol particles traveling on moisture from breathing, coughing, and sneezing. In clinical trials conducted by the U.S. Army, at temperatures between 22 to 28 degrees Celsius at 35 to 65% humidity, the inhaled aerosolized Ebola virus infected 100% of primate study participants suggesting that under some conditions the virus may be airborne (1,2). The Odulair Ebola Isolation Unit exceeds the patient airborne infection isolation requirements in both the number of complete air exchanges per hour and the level of negative pressurization containment.
The Isolation Unit far exceeds the existing level of hospital safety for health care workers by providing a positive pressure protective environment, similar to a surgical theater environment, preventing airborne contaminants and the virus from entering into the medical staff work area. This is the only Ebola Isolation Unit that actively protects the medical staff against known and possible airborne transmission.
CONTACT ODULAIR TO LEARN MORE
1. E. Johnson, N. Jaax, J. White, P. Jahrling. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Path. 1995, 76, 227-236..
2. Elizabeth E. Zumbrun, Holly A. Bloomfield, John M. Dye, Ty C. Hunter, Paul A. Dabisch, Nicole L. Garza, Nicholas R. Bramel, Reese J. Baker, Roger D. Williams, Donald K. Nichols, and Aysegul Nalca. A Characterization of Aerosolized Sudan Virus Infection in African Green Monkeys, Cynomolgus Macaques, and Rhesus Macaques. Viruses 2012, 4, 2115-2136; doi:10.3390/v4102115.